AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39654356
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A, administered every 12 weeks, 155 units total
Trial: 39654356
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered every 12 weeks
Trial: 39654645
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PNS and Transcutaneous Electrical Nerve Stimulation (TENS)
Trial: 39655211
Drug: Dialectical Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavior Therapy Skills Groups (DBT-SG)
Trial: 39655786
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (mandatory transfusion at hemoglobin level ≤10 g/dL)
Trial: 39655786
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (optional transfusion at hemoglobin level ≤8 g/dL)
Trial: 39655790
Drug: CD68-ET3-LV-transduced autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD68-ET3-LV-transduced autologous CD34+ HSCs at doses of 5.0×10
Trial: 39656268
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor blockers (losartan and irbesartan)
Trial: 39656600
Drug: Camrelizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab (200 mg, intravenously) on Day 1 combined with XELOX (oxaliplatin at 130 mg/m2 and capecitabine)
Trial: 39656628
Drug: Runcaciguat (30-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Runcaciguat (30-120 mg once daily, titrated weekly)
Trial: 39656933
Drug: Fluorometholone 0.1%
RxNorm normalized name: FLUOROMETHOLONE 0.1% OINT,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorometholone 0.1% eye drops twice daily for 4 weeks
Trial: 39656933
Drug: Placebo eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drops twice daily for 4 weeks
Trial: 39656951
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus ET
Trial: 39657224
Drug: Liberal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal oxygen strategy (12-15 L of oxygen per minute or fraction of inspired oxygen of 0.6-1.0)
Trial: 39657575
Drug: Palbociclib plus
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib plus letrozole (palbociclib 125 mg on days 1-21 and letrozole 2.5 mg on days 1-28)
Trial: 39657575
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus letrozole (placebo on days 1-21 and letrozole 2.5 mg on days 1-28)
Trial: 39657693
Drug: Contemporary antiretroviral
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Contemporary antiretroviral therapy (ART)
Trial: 39658277
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) administration in high-risk pregnancies
Trial: 39658277
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (previous study comparison group)
Trial: 39658608
Drug: Alternating modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating modified CAPOX (capecitabine 1000 mg/m² and oxaliplatin) plus bevacizumab (anti-VEGF-A antibody)
Trial: 39658608
Drug: Alternating modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating modified CAPIRI (capecitabine and irinotecan) plus bevacizumab (anti-VEGF-A antibody)
Trial: 39658784
Drug: Tailored internet-delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored internet-delivered cognitive behavior therapy (ICBT) for 10 weeks
Trial: 39660140
Drug: Personalized peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized peptide vaccine
Trial: 39660637
Drug: Mepolizumab (anti-interleukin-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (anti-interleukin-5 monoclonal antibody)
Trial: 39661964
Drug: Inhaled long-acting
RxNorm normalized name: Sinex Long-Acting Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled long-acting beta-2 agonists (LABAs)
Trial: 39661964
Drug: Short-acting beta-2
RxNorm normalized name: HUMAN INTERFERON BETA-2
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting beta-2 agonists (SABAs)
Trial: 39662304
Drug: CIT (5.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIT (5.3 g of CIT)
Trial: 39662304
Drug: CMA (5.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMA (5.3 g of CIT, 2.7 g of malate)
Trial: 39662676
Drug: Complementary food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary food supplements (CFSs) with caregiver nutrition counseling
Trial: 39663378
Drug: Seltorexant 40
RxNorm normalized name: Seltorexant
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seltorexant 40 mg
Trial: 39664752
Drug: Oxaloacetate (2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaloacetate (2,000 mg per day)
Trial: 39665235
Drug: ACM-001.1 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACM-001.1 15 mg
Trial: 39665235
Drug: Pindolol 20
RxNorm normalized name: pindolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol 20 mg twice-daily
Trial: 39665235
Drug: ACM-001.1 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACM-001.1 5, 10 or 15 mg twice-daily for 4 days
Trial: 39665378
Drug: Implementation strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation strategies (e.g. educational materials, educational meetings, education outreach visits)
Trial: 39665585
Drug: Guideline-concordant care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-concordant care (surgery with or without radiation therapy; n=473)
Trial: 39665652
Drug: Bedaquiline monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedaquiline monotherapy for 8 weeks
Trial: 39665652
Drug: Standard multidrug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard multidrug therapy (as defined by the World Health Organization) after 8 weeks of bedaquiline
Trial: 39755168
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan (SG) 10 mg/kg on days 1 and 8 of a 21-day cycle
Trial: 39666143
Drug: Eptinezumab treatment
RxNorm normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eptinezumab treatment
Trial: 39666256
Drug: Correct DOAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correct DOAC dosing predictors
Trial: 39666490
Drug: One-to-one music
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-to-one music therapy (MT) intervention for 16 weeks
Trial: 39666578
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline nasal irrigation and gargling (HSNIG) with a 2.6% hypertonic saline solution.
Trial: 39666984
Drug: Highly effective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly effective modulator therapy
Trial: 39666985
Drug: lupus anticoagulant
RxNorm normalized name: Lupus anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lupus anticoagulant
Trial: 39666985
Drug: lupus anticoagulant
RxNorm normalized name: Lupus anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lupus anticoagulant positivity with aD1 and antiphosphatidylserine-prothrombin IgG
Trial: 39667379
Drug: PGT121.414.LS 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGT121.414.LS 3 mg/kg intravenous
Trial: 39667379
Drug: PGT121.414.LS 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGT121.414.LS 10 mg/kg intravenous
Trial: 39667379
Drug: PGT121.414.LS 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGT121.414.LS 30 mg/kg intravenous
Trial: 39667379
Drug: PGT121.414.LS 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGT121.414.LS 5 mg/kg subcutaneous
Trial: 39667379
Drug: PGT121.414.LS 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGT121.414.LS 20 mg/kg intravenous plus VRC07-523LS 20 mg/kg
Trial: 39667379
Drug: PGT121.414.LS 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGT121.414.LS 5 mg/kg subcutaneous plus VRC07-523LS 5 mg/kg
Trial: 39667379
Drug: PGT121.414.LS (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGT121.414.LS (all doses)
Trial: 39667379
Drug: PGT121.414.LS (subcutaneous)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGT121.414.LS (subcutaneous)
Trial: 39667379
Drug: PGT121.414.LS and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGT121.414.LS and VRC07-523LS (higher-dose and dual combination intravenous)
Trial: 39667975
Drug: BAY 81-8973
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 81-8973 (25-50 IU/kg) at least twice weekly
Trial: 39668137
Drug: Nonplatinum chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonplatinum chemotherapy (physician's choice of pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan)
Trial: 39668364
Drug: Traditional movement
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional movement therapy
Trial: 39669115
Drug: Flat flexible
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flat flexible footwear (FFF) added to exercise therapy
Trial: 39669115
Drug: Stable supportive
RxNorm normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable supportive shoes (SSS) added to exercise therapy
Trial: 39669652
Drug: Mild autonomous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild autonomous cortisol secretion (MACS) group (1 mg-DST > 1.8 µg/dL)
Trial: 39669652
Drug: Non-functioning adrenal
RxNorm normalized name: adrenal cortex extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-functioning adrenal tumor group (1 mg-DST ≤ 1.8 µg/dL)
Trial: 39670007
Drug: Imprime PGG
RxNorm normalized name: Imprime PGG
DrugBank: Odetiglucan (DB17468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imprime PGG (4 mg/kg)
Trial: 39670468
Drug: Bavdegalutamide (ARV-110)
RxNorm normalized name: Bavdegalutamide
DrugBank: Bavdegalutamide (DB19032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bavdegalutamide (ARV-110) in combination with abiraterone
Trial: 39671024
Drug: Carbohydrate (CHO)
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO) intake (60 g of maltodextrin + fructose)
Trial: 39671157
Drug: Metformin extended
RxNorm normalized name: metFORMIN Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin extended release up to 750 mg twice daily
Trial: 39671157
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of metformin and LRFM
Trial: 39671174
Drug: Stable gp120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable gp120 vaccine with GLA-SE adjuvant
Trial: 39671174
Drug: Transient gp120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transient gp120 vaccine with GLA-SE adjuvant
Trial: 39671266
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment (control)
Trial: 39671525
Drug: Interlaminar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interlaminar epidural steroid injection + dry needling
Trial: 39671525
Drug: Interlaminar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interlaminar epidural steroid injection + sham dry needling
Trial: 39671525
Drug: Only interlaminar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only interlaminar epidural steroid injection
Trial: 39671543
Drug: Nicotinamide (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (1,500 mg twice a day for 48 weeks)
Trial: 39671573
Drug: Active iTBS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active iTBS intervention (intermittent theta burst stimulation), performed daily, 5 days a week, for 2 weeks.
Trial: 39671752
Drug: CLR 131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLR 131 with external beam radiation therapy (EBRT)
Trial: 39671779
Drug: Early decrease
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early decrease of circulating tumor DNA (ctDNA) ratio after one cycle of neoadjuvant chemotherapy (NACT)
Trial: 39672183
Drug: RH5.1/Matrix-M delayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RH5.1/Matrix-M delayed third-dose regimen
Trial: 39672183
Drug: RH5.1/Matrix-M monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RH5.1/Matrix-M monthly regimen
Trial: 39672515
Drug: Moderately hypofractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately hypofractionated intensity modulated proton therapy (IMPT) with 67.5 Gy to prostate/seminal vesicles and 45 Gy to pelvic lymph nodes in 25 daily fractions, all received androgen deprivation therapy.
Trial: 39672984
Drug: Medically tailored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medically tailored meals (MTM) with medical nutrition therapy (MNT) - home delivery of 12 medically tailored frozen meals and a fresh produce bag weekly for 3 months, plus monthly calls with a registered dietitian for 6 months.
Trial: 39672984
Drug: Medically tailored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medically tailored meals (MTM) with medical nutrition therapy (MNT)
Trial: 39673171
Drug: High-dose denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: High-dose denosumab (120 mg/month with loading doses on weeks 2 and 3) for 6 months
Trial: 39673171
Drug: Moderate-dose denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Moderate-dose denosumab (120 mg/3 months)
Trial: 39673298
Drug: Daily coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily coffee consumption (>5 cups/day)
Trial: 39673298
Drug: Daily coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily coffee consumption (<1 cup/day)
Trial: 39673334
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy, 2.5 mg subcutaneous injections daily from Day 1 of ovarian stimulation until oocyte retrieval
Trial: 39673334
Drug: Standard ovarian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ovarian stimulation without adjuvant therapy (Control)
Trial: 39673415
Drug: Guselkumab 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 400 mg intravenous infusion at Weeks 0, 4, and 8, followed by 200 mg subcutaneous injections at Week 12 and every 4 weeks through Week 48, in addition to background therapy.
Trial: 39673415
Drug: Placebo intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous infusion at Weeks 0, 4, and 8, followed by placebo subcutaneous injections at Week 12 and every 4 weeks through Week 48, in addition to background therapy.
Trial: 39673415
Drug: Guselkumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab + background therapy
Trial: 39673415
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + background therapy
Trial: 39673447
Drug: Talimogene laherparepvec
RxNorm normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Talimogene laherparepvec (T-VEC) via endoscopic injection
Trial: 39673452
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg (≥ 60 kg) or 200 mg (≥ 20 to < 60 kg) subcutaneously every 2 weeks for 24 weeks
Trial: 39673591
Drug: Oral triapine
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral triapine (100 mg, five days a week for five weeks) with weekly IV cisplatin chemoradiation
Trial: 39673746
Drug: Oral vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vancomycin (OV) 125mg QID for 4 weeks
Trial: 39673810
Drug: Niraparib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib at individualized starting dose (ISD) 200 mg/day
Trial: 39674398
Drug: IMI/REL (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMI/REL (500 mg/250 mg) every 6 h for 7-14 days
Trial: 39674398
Drug: PIP/TAZ (4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIP/TAZ (4000 mg/500 mg) every 6 h for 7-14 days
Trial: 39675486
Drug: Dapagliflozin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin plus metformin
Trial: 39675486
Drug: Dapagliflozin and
RxNorm normalized name: Dapagliflozin and metformin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin and metformin dual-therapy
Trial: 39675486
Drug: Dapagliflozin and
RxNorm normalized name: Dapagliflozin and metformin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin and metformin combination therapy
Trial: 39675821
Drug: Comprehensive phenotypic
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive phenotypic evaluation including age, antibodies against glutamic acid decarboxylase, body mass index, glycated haemoglobin (HbA1c), indexes of insulin sensibility (HOMA2-IR) and secretion (HOMA2-beta)
Trial: 39676137
Drug: SHR-1701 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1701 (30 mg/kg), bevacizumab (7.5 mg/kg), and oxaliplatin (130 mg/m2)
Trial: 39676465
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment for at least 2 years
Trial: 39676687
Drug: ESO-101 (mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESO-101 (mometasone furoate, 800 μg)
Trial: 39676868
Drug: IAH0968 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAH0968 (6 mg/kg, 10 mg/kg)
Trial: 39679349
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose of 50 µg mRNA-1273
Trial: 39679349
Drug: 15-month dosing
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15-month dosing interval
Trial: 39679566
Drug: Nonablative bipolar
RxNorm normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonablative bipolar radiofrequency treatment
Trial: 39680321
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intravenous vitamin K1
Trial: 39680515
Drug: Adjunctive Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive Steroid Combination in Ocular Trauma (ASCOT)
Trial: 39681126
Drug: Drug-level feedback
RxNorm normalized name: MENTHOL, UNSPECIFIED FORM 100 mg in 1 g TOPICAL GEL [Evel Knievels Natural Choice Pain Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-level feedback counselling
Trial: 39681126
Drug: Monthly counselling
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly counselling
Trial: 39681752
Drug: Intraoral injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRADURAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoral injection technique
Trial: 39681752
Drug: Extraoral injection
RxNorm normalized name: Extraneal Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraoral injection technique
Trial: 39681893
Drug: Daily cellphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily cellphone access among non-cellphone owners
Trial: 39681895
Drug: Nthabi conversational
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nthabi conversational agent system for folic acid use education
Trial: 39683633
Drug: 630 mg
RxNorm normalized name: attapulgite 630 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 630 mg A-GPC (HD)
Trial: 39683633
Drug: 315 mg
RxNorm normalized name: guaifenesin 315 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 315 mg A-GPC (LD)
Trial: 39686620
Drug: Gantenerumab (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gantenerumab (up to 1200 mg every 4 weeks)
Trial: 39686647
Drug: Steroids alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids alone or in combination with immunosuppressive drugs and/or IVIg